Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside [Seeking Alpha]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Seeking Alpha
full-year earnings outlook on the back of a strong first-quarter revenue beat, and t he results reinforce why the company sits near the very Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights AbbVie has strong revenue, increased earnings outlook, scale, diversification, and robust fundamentals compared to Buy-rated peers. Quant Ratings assess stocks based on valuation, growth, momentum, and profitability to give bullish or bearish scores from 1 to 5. Moderna leads in price performance with +59.85% year-to-date, followed by Relay Therapeutics at +54.02%. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026GlobeNewswire
- Relay Therapeutics (RLAY) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $17.00 to $19.00. They now have a "market outperform" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- RLAY's page on the SEC website